CorMatrix® Cardiovascular, Inc. Receives Two (2) Additional U.S. Patents for ECM® Biomaterial Compositions

Roswell, GA – June 16, 2015 – CorMatrix® Cardiovascular, Inc., a leading developer of biomaterial compositions and medical devices, today announced the issuance of U.S. Patent No. 9,034,367 entitled Articles for Tissue Regeneration with Biodegradable Polymers. The ‘367 patent covers grafts and compositions comprising a variety of extracellular matrix (ECM®) materials, including small intestine submucosa, stomach submucosa, liver basement membrane and urinary bladder submucosa. ECM® biopolymer grafts and compositions can also include supplemental bioactive agents, such as growth factors, cells, and other pharmacological agents.

A biodegradable polymer is useful to the creation of devices because it will hold an anatomically correct shape and retain a presence for a temporary period of time. This, when combined with CorMatrix ECM platform technology, would enable new tissue to conform to a device while maintaining a position or shape during remodeling; and would remain until it is strong enough to fully support its new application in the body.

“The addition of various compositions of polymers in combination with the CorMatrix® platform of ECM® materials further broadens our potential applications. The compositions and devices that we are creating are unique in their cardiovascular and non-cardiovascular applications” said Dr. Robert Matheny, Chief Scientific Officer and co-founder of CorMatrix®, “This patent enables us to pursue the ideal biomaterial—one that leaves no trace, is easily processed into its final anatomical product form, one that demonstrates acceptable shelf life, and is easily sterilized.”

The ideal polymer for a particular application requires configuration such that its mechanical and degradation properties match that of the application, remaining sufficiently strong until the surrounding tissue has healed. Historically, the use of traditional polymers has been disregarded due to inflammatory and toxic responses, and are not metabolized by the body after fulfilling their purpose.

The U.S. Patent and Trademark Office has also recently granted CorMatrix® U.S. Patent No. 9,034,647 for another injectable extracellular matrix (ECM®) bioscaffold. The augmented ECM® bioscaffold, which includes an exogenously added cytokine, induces stem cell proliferation and differentiation of stem cells into cardiomyocytes, and, thereby, angiogenesis and remodeling, i.e. tissue repair, of cardiovascular tissue. The ‘647 patent represents a growing number of multiple CorMatrix® U.S. and foreign patents with claims directed to ECM® bioscaffolds that are augmented with a variety of bioactive agents, such as TGF-α, TGF-β and RNA.

“These recently issued patents emphasize the drive, determination and vision of our people and our organization,” said David Camp, CEO and co-founder of CorMatrix. “With this and other investments in U.S. and foreign patent applications, we’ll continue to drive novel ECM® based compositions aimed at extending our CorMatrix® platform and permanently changing the medical device industry.”

CorMatrix is poised to successfully expand its current line of product offerings with over 275 pending U.S. and foreign patent applications. In the last two years alone, fifty-one (51) U.S. and foreign patents have issued for CorMatrix’s ECM® based compositions and structures.